Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial

Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial Publisher Pubmed

Saadati S¹ ; Sadeghi A² ; Mansour A¹ ; Yari Z¹ ; Poustchi H³ ; Hedayati M⁴ ; Hatami B² ; Hekmatdoost A¹

Show Affiliations

1. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Liver and Pancreatobiliary Research Group, Digestive Disease Research Institute, Tehran, Iran
4. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: BMC Gastroenterology Published:2019

Abstract

Background: The aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD). Methods: Fifty patients with NAFLD were randomized to receive lifestyle modification advice plus either 1500 mg curcumin or the same amount of placebo for 12 weeks. Results: Curcumin supplementation was associated with significant decrease in hepatic fibrosis (p < 0.001), and nuclear factor-kappa B activity (p < 0.05) as compared with the baseline. Hepatic steatosis and serum level of liver enzymes, and tumor necrosis-α (TNF-α) significantly reduced in both groups (p < 0.05). None of the changes were significantly different between two groups. Conclusion: Our results indicated that curcumin supplementation plus lifestyle modification is not superior to lifestyle modification alone in amelioration of inflammation. Trial registration: IRCT20100524004010N24, this trial was retrospectively registered on May 14, 2018. © 2019 The Author(s).

Related Docs

View other Related Docs

1. The Effects of Curcumin Supplementation on Liver Enzymes, Lipid Profile, Glucose Homeostasis, and Hepatic Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease, European Journal of Clinical Nutrition (2019)

2. Legume Intake and Risk of Nonalcoholic Fatty Liver Disease, Indian Journal of Gastroenterology (2019)

3. Egg Consumption and Risk of Non-Alcoholic Fatty Liver Disease, World Journal of Hepatology (2017)

4. Association of Allium Vegetables Intake and Non-Alcoholic Fatty Liver Disease Risk: A Case-Control Study, Nutrition and Food Science (2020)

5. Hesperidin Improves Hepatic Steatosis, Hepatic Enzymes, and Metabolic and Inflammatory Parameters in Patients With Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial, Phytotherapy Research (2019)

6. The Association Between Dietary Acid Load and Odds of Non-Alcoholic Fatty Liver Disease: A Case-Control Study, Nutrition and Health (2023)

7. Galactose Intake Is Related to Nonalcoholic Fatty Liver Disease, Nutrition and Food Science (2019)

8. Adherence to the Dietary Approaches to Stop Hypertension (Dash) and Risk of Nonalcoholic Fatty Liver Disease, International Journal of Food Sciences and Nutrition (2016)

Experts (# of related papers)

View all Related Experts

Hossein Poustchi (13)

Mohammad Javad Hosseinzadeh Attar (4)

Style	Citing Format
MLA	Saadati S, et al.. "Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial." BMC Gastroenterology, vol. 19, no. 1, 2019, pp. -.
APA	Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A (2019). Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial. BMC Gastroenterology, 19(1), -.
Chicago	Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A. "Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial." BMC Gastroenterology 19, no. 1 (2019): -.
Harvard	Saadati S et al. (2019) 'Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial', BMC Gastroenterology, 19(1), pp. -.
Vancouver	Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, et al.. Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial. BMC Gastroenterology. 2019;19(1):-.
BibTex	@article{ author = {Saadati S and Sadeghi A and Mansour A and Yari Z and Poustchi H and Hedayati M and Hatami B and Hekmatdoost A}, title = {Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial}, journal = {BMC Gastroenterology}, volume = {19}, number = {1}, pages = {-}, year = {2019} }
RIS	TY - JOUR AU - Saadati S AU - Sadeghi A AU - Mansour A AU - Yari Z AU - Poustchi H AU - Hedayati M AU - Hatami B AU - Hekmatdoost A TI - Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial JO - BMC Gastroenterology VL - 19 IS - 1 SP - EP - PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract